Back to Awarded Treatment Trials
Awarded Trial: 03T-294
Grant ID
03T-294
Illness
Schizophrenia
Primary Drug/Intervention
Reboxetine
Primary Dosage
2mg b.i.d.
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
Olanzapine
Other Dosage
10mg
Status
Completed
Investigator
Poyurovsky
Sample Size
60
Duration of Study Period for Each Subject
8 weeks
Outcome Measurements
Body weight, body mass index, SAPS, SANS, HDRS
Results
Patients receiving olanzapine were randomized to receive adjunctive reboxetine (a selective norepinephrine re-uptake inhibitor) or placebo in an effort to prevent excessive weight gain. Patients receiving reboxetine gained less weight than the placebo group (mean = 1.3kg) but the results did not achieve statistical significance. The addition of reboxetine also did not appear to improve ratings of psychiatric symptoms.
Publication
N/A
Link
N/A
PI Name
Michael Poyurovsky
Degree
MD
Center
Rappaport Faculty of Medicine, Technion Institute of Technology
Institution
Tirat Carmel Mental Health Center
Address
9 Eshkol Street
City or Town
Tirat Carmel
State or Province
N/A
Zip or Postal Code
30200
Country
Israel
Email Address
trymichael@matat.health.gov.il